Publications by authors named "Kamali Chance"

Claim this Profile
F
FDA Expectations for Demonstrating Interchangeability.
Kamali Chance

Ther Innov Regul Sci· May 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pharmacokinetic equivalence, comparable safety, and immunogenicity of an adalimumab biosimilar product (M923) to Humira in healthy subjects.
Jan Hillson, Tim Mant, Molly Rosano, Carolyn Huntenburg, Mehrshid Alai-Safar, Kamali Chance

Pharmacol Res Perspect· February 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Challenges With the Development of Biosimilars in Asia for Western Markets: An Overview and Suggested Solutions.
Raymond A Huml, Oxana Iliach, Kamali Chance, Nigel R Rulewski

Ther Innov Regul Sci· March 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Biosimilars in rheumatology: understanding the rigor of their development.
Niti Goel, Kamali Chance

Rheumatology (Oxford)· February 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis